Bio-Rad Laboratories BIO Clinical Diagnostics — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's clinical diagnostics — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's clinical diagnostics — gross profit?
- Bio-Rad Laboratories (BIO) reported clinical diagnostics — gross profit of $181.8M in Q1 2026.
- How has Bio-Rad Laboratories's clinical diagnostics — gross profit changed year-over-year?
- Bio-Rad Laboratories's clinical diagnostics — gross profit increased by 2.4% year-over-year, from $177.6M to $181.8M.
- What is the long-term trend for Bio-Rad Laboratories's clinical diagnostics — gross profit?
- Over 3 years (2022 to 2025), Bio-Rad Laboratories's clinical diagnostics — gross profit has grown at a 1.4% compound annual growth rate (CAGR), from $754.5M to $786.8M.
- What does clinical diagnostics — gross profit mean?
- Revenue from diagnostics minus the direct costs to produce those goods.
- How do you interpret clinical diagnostics — gross profit?
- Higher gross profit indicates strong pricing power or efficient production processes.
- How does clinical diagnostics — gross profit compare across companies?
- A key indicator of competitive advantage and product pricing power in the diagnostics industry.